In many countries, immunohistochemistry-based assessment of Ki67 is part of the routine biomarker evaluation of breast cancers along with estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2). This evidence concerns the gene ESR1 and breast cancer.